China approved Shanghai Fosun Pharmaceutical (HKG:2196, SHA:600196) subsidiary Shanghai Fosun Pharmaceutical Industrial Development's tenapanor hydrochloride tablets for an indication of chronic kidney disease, according to a Wednesday filing with the Hong Kong Exchange.
The tablets help control serum phosphorus levels in dialysis patients with chronic kidney disease who do not have an adequate response to phosphorus binders, the filing said.
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.